Long-Term Dupilumab for AD Evaluated in Cohort Study

Dermatitis News

Long-Term Dupilumab for AD Evaluated in Cohort Study
Atopic DermatitisAtopic EczemaPruritus
  • 📰 Medscape
  • ⏱ Reading Time:
  • 17 sec. here
  • 31 min. at publisher
  • 📊 Quality Score:
  • News: 111%
  • Publisher: 55%

Dupilumab maintained its effectiveness in patients with atopic dermatitis for up to 5 years, with adverse events and ineffectiveness being the primary reasons for discontinuation, in a cohort study reflecting daily practice.

Dupilumab remained effective in most patients with atopic dermatitis up to 5 years, although nearly a quarter of patients in the cohort study discontinued treatment because of adverse events and/or ineffectiveness, researchers report.A prospective multicenter cohort study evaluated 1286 patients with AD from the BioDay registry in the Netherlands treated with dupilumab between October 2017 and December 2022.

The median follow-up time was 87.5 weeks; patients were seen at baseline, 4 weeks, and then every 3-6 months. Most patients achieved an EASI score ≤ 7 at 16 weeks, as did 12 of the 17 patients evaluated at 5 years. After 16 weeks, 71.2% of patients achieved NRS scores for pruritus ≤ 4, as did 15 of the 17 evaluated at 5 years.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Medscape /  🏆 386. in US

Atopic Dermatitis Atopic Eczema Pruritus Pruritis Itch Children Child Childhood Pediatrics Kids Chemokines Eosinophils Eosinophil Granulocytes Thymic Artificial Intelligence Deep Learning AI NPL Machine Learning ML Natural Language Processing Artificial Neural Networks Eczema Geriatrics Elder Care Geriatric Medicine Older Adults Seniors Senior Citizens Elderly

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

State’s first long-term medical home for kids to open at long last in 2025State’s first long-term medical home for kids to open at long last in 2025Following delays and scrutiny over funding and location, construction of Mississippi's first skilled pediatric facility is underway.
Read more »

Lebrikizumab Compared With Dupilumab in Atopic DermatitisLebrikizumab Compared With Dupilumab in Atopic DermatitisLebrikizumab and dupilumab showed similar efficacy in patients with atopic dermatitis, with some small differences, in a meta-analysis.
Read more »

Dupilumab Safe, Effective Over 5 Years in Moderate to Severe Atopic DermatitisDupilumab Safe, Effective Over 5 Years in Moderate to Severe Atopic DermatitisLong-term data confirm safety and efficacy of dupilumab treatment, which offered sustained efficacy without any new safety incidents in patients with moderate to severe AD.
Read more »

Review Finds Dupilumab Benefits Kids With Atopic Dermatitis and AlopeciaReview Finds Dupilumab Benefits Kids With Atopic Dermatitis and AlopeciaDupilumab treatment was associated with improved hair growth and reduced severity of atopic dermatitis in a review.
Read more »

Lemurs use long-term memory, smell, and social cues to find foodLemurs use long-term memory, smell, and social cues to find foodHow do foraging animals find their food? A new study by New York University researchers shows that lemurs use smell, social cues, and long-term memory to locate hidden fruit—a combination of factors that may have deep evolutionary roots.
Read more »

Risk-Reducing Oncology Surgery: Discussing Short- and Long-Term Effects With PatientsRisk-Reducing Oncology Surgery: Discussing Short- and Long-Term Effects With PatientsDr Maurie Markman discusses the important conversations required about both short- and long-term effects when discussing risk-reducing surgery with patients.
Read more »



Render Time: 2025-02-13 05:23:54